SLT study as first-line or second-line treatment for NTG

SLT study as first-line or second-line treatment for NTG - SLT as first-line or second-line treatment for NTG

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000039232

Enrollment

100

Registered

2020-01-24

Start date

2020-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

glaucoma

Interventions

A period of the intervention for the individual subject: One year Quantity (a dose or dose of radioactivity): 0.8mJ *90 The number of times, frequency: Only once, first-line A period of the interven

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The treatment that SLT treatment (first-line SLT treatment or second-line SLT treatment) is most suitable and the case that were judged intraocular pressure>= 14mmHg and MD>= -15dB more than at least one time in three times most recent in patients of NTG Cornea thickness 450-600 Age at the time of the agreement acquisition 20 years old or older

Exclusion criteria

Exclusion criteria: Using glaucoma eye drops more than two drugs (including the combination agent), and there is not a plan of the discontinuation at all anymore Past of the laser treatment Past of LASIK Past of eye surgeries (but is excluded when is more than 3 months after cataract surgery)

Design outcomes

Primary

Measure	Time frame
We may supplement instillation treatment by investigating the effect, safety of first-line SLT and the second-line SLT for NTG.	—

Countries

Japan

Contacts

Public ContactKoji Nitta

Fukui-ken saiseikai Hospital Ophthalmology

nitta.koji7001@fukui.saiseikai.or.jp0776-23-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026